Gamelin Erick — SEC Form 4 filings
SEC reporting owner CIK 1950551. 15 Form 4 filings on record with FilingPulse; latest filed 2026-08-20.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-02-16 to 2026-08-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 400 shares, $804 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 400 shares @ $2.01 ($804) in Acrivon Therapeutics, Inc., filed 2026-08-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | Chief Development Officer | 15 | — | 1 leg · 400 sh · $804 | 14 |
Form 4 filings — Gamelin Erick
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Sale (S): 400 @ $2.01 | EDGAR |
| 2026-05-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 38,584 @ $0 | EDGAR |
| 2026-05-18 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 404 @ $1.92 | EDGAR |
| 2026-03-03 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 94,946 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 471 @ $1.63 | EDGAR |
| 2025-11-18 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 403 @ $2.24 | EDGAR |
| 2025-08-18 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 403 @ $1.39 | EDGAR |
| 2025-05-16 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 403 @ $1.14 | EDGAR |
| 2025-03-04 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 78,078 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 469 @ $5.42 | EDGAR |
| 2024-11-27 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 45,045 (derivative) @ $0 | EDGAR |
| 2024-11-18 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 402 @ $7.92 | EDGAR |
| 2024-08-16 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 402 @ $7.02 | EDGAR |
| 2024-05-16 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 402 @ $8.36 | EDGAR |
| 2024-02-16 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Tax withholding (F): 468 @ $3.40 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1950551 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →